CorpDigest
Novo Nordisk A/S
Leadership History
4 leaders · Full leadership timeline
Last reviewed: 2026-06-08 · By Swet Parvadiya
A single molecule generated 215.2 billion Danish Krone in FY2024 sales. Semaglutide — marketed as Ozempic for diabetes and Wegovy for obesity — is the most commercially successful pharmaceutical product of the current decade and possibly the most consequential medicine introduced since statins. Novo Nordisk generated 290.42 billion DKK (approximately $42.7 billion) in total FY2024 revenue, and 74% of that revenue came from one chemical compound first synthesized by the company's researchers. That concentration is simultaneously the source of extraordinary financial performance and the central strategic risk of the entire enterprise. Novo Nordisk's origins in 1923 and 1925 as two separate Danish insulin laboratories trace back to August Krogh, a Danish Nobel laureate who learned of insulin's discovery in Canada in 1922 and obtained a license to manufacture it in Scandinavia. For eight decades, the company operated as a high-quality but relatively constrained insulin manufacturer competing in a global market where Eli Lilly, Sanofi, and others were similarly positioned. The incretin class of drugs — GLP-1 receptor agonists that stimulate insulin secretion while suppressing appetite — changed everything. Semaglutide, the optimized GLP-1 agonist that Novo Nordisk developed over fifteen years of research, proved effective not just for blood sugar control but for substantial, sustained weight loss. The company operates from Bagsværd, Denmark, a suburb of Copenhagen where the research and manufacturing infrastructure that produced semaglutide was built over decades. The 77,900 employees across global manufacturing facilities cannot produce Wegovy and Ozempic fast enough to meet demand — a problem that is simultaneously evidence of unprecedented commercial success and a constraint on revenue growth. Novo Holdings, the controlling shareholder, acquired Catalent in 2024 for $16.5 billion specifically to secure additional manufacturing capacity. CEO Lars Fruergaard Jørgensen has been managing a company that grew from $24.8 billion in FY2022 revenue to $42.7 billion in FY2024 — 72% growth in two years — while simultaneously trying to build the manufacturing infrastructure to support a demand trajectory that no pharmaceutical company in history had previously experienced.
Chief Executive Officer
Jørgensen executed the strategic pivot toward GLP-1 receptor agonists and obesity therapeutics, overseeing the launch of Ozempic and Wegovy. He has also managed the massive 28.6 billion DKK capital expenditure program to expand global manufacturing capacity and the $16.5 billion Catalent acquisition to secure fill-finish capacity.
Chief Financial Officer
Nielsen managed the financial aspects of the company's explosive growth, including the capital allocation strategy for the massive R&D and manufacturing investments. He played a key role in maintaining the company's strong credit rating and investor confidence during the transition to a pure-play incretin model.
Executive Vice President, Research and Development
Lange leads the company's global R&D organization, overseeing a 34.6 billion DKK annual budget and a pipeline of over 100 clinical projects. He has been instrumental in advancing the semaglutide franchise and expanding the company's presence in cardiovascular outcomes and rare diseases.
Executive Vice President, Commercial
Green is responsible for driving the company's global commercial strategy, including the launch of Wegovy and the navigation of the complex PBM rebate landscape in the US. He has led the expansion of the sales force and the implementation of data-driven commercial execution strategies.
To counter this threat, Novo Nordisk has initiated a massive pipeline expansion, securing exclusive rights to Zealand Pharma's amycretin program and advancing CagriSema, a combination of semaglutide and the long-acting amylin analog cagrilintide, which has demonstrated 22.7% weight loss in Phase II trials. This concentration of risk is mirrored by a concentration of reward, as the company no longer dilutes its returns with the low-margin, highly competitive diabetes care portfolio, allowing it to deploy its massive free cash flow toward high-risk, high-reward acquisitions and share buybacks. This franchise is split between Ozempic (146.9 billion DKK), indicated for type 2 diabetes and cardiovascular risk reduction, and Wegovy (68.2 billion DKK), indicated for chronic weight management. The most significant competitive threat, however, comes from the rise of oral small molecule GLP-1 agonists and amylin analogs.
Amgen's mariTide, an antibody-peptide conjugate that targets the GLP-1 receptor with a monthly dosing schedule, represents a particularly disruptive threat, as it could potentially capture the significant segment of the market that is averse to weekly injections. The competitive narrative in cardiovascular outcomes is equally dynamic, with the rapid emergence of SGLT2 inhibitors and non-steroidal MRAs threatening to displace GLP-1s as the standard of care for cardiorenal protection. This competitive threat is not merely theoretical; it is reflected in the FY2024 prescription volume data, where Zepbound's weekly US prescription counts have consistently outpaced Wegovy's, eroding Novo Nordisk's historical dominance in the obesity market. The company's response to these challenges has been to pivot aggressively toward next-generation multi-receptor agonists and oral formulations, but this pivot requires massive capital expenditure and carries high binary clinical risk.
Novo Nordisk has had four CEOs since the 1989 merger of Novo and Nordisk. Mads Øvlisen, who had been CEO of Novo Industri prior to the merger, served as CEO of the combined Novo Nordisk from 1989 through November 2000 — an eleven-year tenure that established the company's post-merger commercial and R&D structure. Lars Rebien Sørensen succeeded Øvlisen in November 2000 and served as CEO through January 2017 — a sixteen-year tenure that included the launch of the modern GLP-1 franchise (Victoza approved 2009), the development and approval of semaglutide as Ozempic in 2017, and the expansion of the company from approximately DKK 23 billion to DKK 112 billion in revenue. Sørensen was widely recognized for strategic patience, including the multi-decade investment in GLP-1 research that ultimately produced semaglutide. He stepped down as CEO and is currently Chair of the Novo Nordisk Foundation. Lars Fruergaard Jørgensen succeeded Sørensen on January 1, 2017 and has served continuously since. In April 2025 Jørgensen announced his decision to step down later in 2025, with the board initiating a CEO succession process. The CEO transitions have all been internal, smooth, and reflect the long-cycle nature of pharma leadership and the Novo Nordisk Foundation's preference for continuity.
Lars Rebien Sørensen led Novo Nordisk from November 2000 through January 2017 — sixteen years that transformed the company from a Danish insulin specialist into a top-ten global pharmaceutical company. Revenue grew from approximately DKK 23 billion in 2000 to DKK 112 billion in 2016, and market capitalization grew from approximately $20 billion to over $100 billion. Sørensen's signature strategic moves included three threads. First, the multi-decade investment in GLP-1 research: Sørensen sustained and expanded the GLP-1 program through liraglutide (Victoza approved 2009) and into semaglutide (approved as Ozempic in December 2017, after Sørensen's departure but during a development period he managed). Second, the expansion of the obesity franchise: Saxenda (high-dose liraglutide) was approved in 2014 for chronic weight management, establishing Novo Nordisk's commercial presence in obesity ahead of competitors. Third, the global commercialization buildout: Sørensen oversaw the expansion of Novo Nordisk's salesforce and commercial infrastructure across the US (where Novo Nordisk's Princeton, New Jersey US headquarters became a major operation), China, and emerging markets. Harvard Business Review named Sørensen the world's best-performing CEO in 2015 and 2016 based on long-run TSR. He has served as Chair of the Novo Nordisk Foundation since 2017.
Lars Fruergaard Jørgensen became CEO of Novo Nordisk on January 1, 2017, succeeding Lars Rebien Sørensen. A Danish economist who joined Novo Nordisk in 1991 and held senior roles in IT, business development, and corporate strategy before becoming CEO at age 50, Jørgensen took over at a strategically critical inflection point — semaglutide had been approved as Ozempic in December 2017 but the magnitude of the GLP-1 opportunity was not yet apparent. His priorities have centered on four themes. First, executing the semaglutide commercial launch globally across diabetes (Ozempic), oral diabetes (Rybelsus 2019), and obesity (Wegovy 2021), with Wegovy in particular requiring novel commercial infrastructure including direct-to-consumer awareness and payer-engagement strategies. Second, manufacturing capacity expansion to meet GLP-1 demand: under Jørgensen, capital expenditures grew from DKK 8 billion in 2020 to over DKK 35 billion in 2024 supporting expansions in Kalundborg (Denmark), Clayton (North Carolina), Hillerød (Denmark), Chartres (France), and the 2024 Catalent fill-and-finish acquisition. Third, pipeline diversification through M&A: Emisphere ($1.8B 2020), Dicerna ($3.3B 2021), Forma ($1.1B 2022), and Cardior ($1.1B 2024) extended Novo Nordisk's technological breadth. Fourth, managing US political and pricing pressure: Jørgensen testified before the September 2024 Senate HELP Committee on GLP-1 pricing. In April 2025 he announced his decision to step down as CEO.
On April 12, 2025 Novo Nordisk announced that Lars Fruergaard Jørgensen would step down as CEO during 2025 at the board's direction, citing the need for new leadership during the company's next chapter following the CagriSema Phase III disappointment in December 2024 and the share-price retracement that followed. The decision was unusual in the context of Novo Nordisk's historically smooth and patient leadership transitions, and reflected board-level concern about the competitive pressure from Eli Lilly's tirzepatide and the slower-than-expected ramp of the CagriSema and amycretin pipeline programs. Jørgensen will remain CEO until a successor is appointed and through a transition period. The board chair Helge Lund, who took the role in 2024, has led the succession process in coordination with Novo Holdings and the Novo Nordisk Foundation. Candidate profiles being discussed publicly have included internal candidates (Maziar Mike Doustdar, executive vice president for International Operations) and external candidates. The succession is the first CEO transition under direct board-driven pressure in Novo Nordisk's history and reflects the heightened scrutiny that the GLP-1 franchise and the obesity-medicine competitive dynamics now face. The strategic direction is expected to continue emphasizing GLP-1 leadership, manufacturing capacity, and pipeline diversification regardless of the new CEO's specific background.